Study to Assess the Effect of Gabapentin Enacarbil on Simulated Driving in Healthy Subjects

Phase 1

Completed

• Conditions: Restless Legs Syndrome (RLS)
• Interventions: Drug: gabapentin enacarbil; Drug: diphenhydramine; Drug: placebo

• Registration Number: NCT01411124
• Lead Sponsor: XenoPort, Inc.

Brief Summary

This is a double-blind, placebo-and active-controlled 3-period crossover study designed to assess the effect of GEn 600 mg on simulated driving performance in healthy volunteers.

Detailed Description

proportional systemic gabapentin exposure over a wide dose range. This is a double-blind, placebo-and active-controlled 3-period crossover study designed to assess the effect of GEn 600 mg on simulated driving performance. Subjects will receive each of 3 treatments in a randomized order: GEn 600 mg, placebo and placebo/diphenhydramine 50 mg. Each treatment period will consist of 6 days, with subjects being dosed at approximately 5 pm on each dosing day. The placebo /diphenhydramine treatment will consist of placebo on Days 1-4 and 6 and 50 mg diphenhydramine on Day 5. Placebo will be administered on Day 6 in all treatment periods to ensure washout of drug prior to the start of the next treatment period. Simulated driving performance will be assessed at baseline (prior to randomization) and on Day 5 in the evening (7-9 pm) and on Day 6 between7-9 am and between 11am-1pm for each treatment period.

Study Timeline

• Study Start: 2011-06
• Study First Submitted: 2011-07-28
• Study First Submitted QC: 2011-08-04
• Study First Posted: 2011-08-08
• Primary Completion: 2011-10
• Study Completion: 2011-10
• Status Verified: 2011-11
• Last Update Submitted: 2013-07-15
• Last Update Posted: 2013-07-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

• Healthy as determined by a responsible physician, based on a medical evaluation including medical history, physical examination, laboratory tests and ECG. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures
• Male or female between 18 and 65 years of age, at the time of signing the informed consent.
• A female subject is eligible to participate if she is of Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation at least 6 months previously or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 MlU/mL and estradiol < 40 pg/mL (<140 pmol/L) is confirmatory]. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods in Section 8.1 if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method.Child-bearing potential and agrees to use one of the contraception methods listed in Section 8.1 for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until the follow-up visit is completed.
• Body weight > 50 kg and Body Mass Index (BMI) within the range 19 - 30 kg/m2 (inclusive)
• Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form
• QTcB < 450 msec
• Creatinine clearance (CrCl) >80 mL/min. CrCl is estimated using the equation of Cockcroft and Gault. See study procedure manual for details on creatinine clearance calculations.
• AST, ALT, alkaline phosphatase and bilirubin >1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%)
• Currently a licensed, experienced driver who drives at least 3 times a week for the past 3 years and with visual acuity assessed by the investigator as being adequate for driving
• Able to complete a 1 hour simulated driving test and demonstrate satisfactory driving skills at screening

Exclusion Criteria

• The subject has a positive pre-study drug/alcohol screen. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines
• A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
• A positive test for HIV antibody
• History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >14 drinks/week for men or >7 drinks/week for women. One drink is equivalent to (12 g alcohol) = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of 80 proof distilled spirits.
• The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
• Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
• Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety
• History of sensitivity to gabapentin, DPH or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation
• Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period
• Pregnant females as determined by positive serum human chorionic gonadotrophin (hCG) test at screening or prior to dosing
• Lactating females
• Unwillingness or inability to follow the procedures outlined in the protocol
• The subject has a screening heart rate <50 or >100 bpm or a systolic blood pressure >140 or <100 mmHg or a diastolic blood pressure >90 or <60 mmHg in the semi-supine position after at least 3 minutes of rest.
• Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 3 months prior to screening
• History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic or psychiatric disease
• History of seizures other than febrile seizures as a child
• Subjects who have received any medications known to chronically alter drug absorption or elimination processes within 30 days of the first dose administration, in the opinion of the Sponsor or Investigator
• Subjects with a creatine kinase (CK) value of greater than the upper limit of normal that is not explainable by recent strenuous exercise and the value does not return within normal range upon retest
• Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
• Subject is mentally or legally incapacitated
• Subjects with a sleep disorder e.g. sleep apnea, narcolepsy or primary insomnia
• Shift workers who are not on normal day/night sleep cycles
• Subjects with a history of closed angle glaucoma, urinary retention or other conditions for which DPH is contra-indicated
• Has active suicidal plan/intent or has had active suicidal thoughts in the past 6 months. Has history of suicide attempt in the last 2 years or more than 1 lifetime suicide attempt
• Subjects who have consumed an average of > 5 cups of caffeinated beverages per day within 20 days of the screening visit

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
diphenhydramine	placebo	50 mg
placebo	placebo	placebo to match
Gabapentin Enacarbil	gabapentin enacarbil	600 mg of Gabapentin Enacarbil
Gabapentin Enacarbil	placebo	600 mg of Gabapentin Enacarbil
diphenhydramine	diphenhydramine	50 mg

Primary Outcome Measures

Name	Time	Method
Lane performance Variability	From Day-1 baseline to end of treatment. Participants will be followed for the duration of the clinic visit an average of 3 weeks.	change from baseline in lane position variability

Secondary Outcome Measures

Name	Time	Method
Change in Speed Variability	from baseline to end of treatment Participants will be followed for the duration of the clinic visit an average of 3 weeks	Change from baseline in speed variability
number of simulated crashes	on Days 5 and 6. The subjects will be followed for the duration of the clinic visit an average of 3 week	number of simulated crashes
Visual Analog Scale	Baseline to end of treatment. The subjects will be followed for the duration of the clinic visit an average of 3 weeks	Pre driving alterness measured by the Visual analog scale
Visual analog scale on post driving alertness	baseline to days 5 and 6. The subjects will be followed for the duration of the clinic visit an average of 3 weeks	Post driving alterness measured by visual alterness scale
Visual Analog scale of the difference between pre and post driving alertness	baseline to days 5 and 6. The subjects will be followed for the duration of the clinic visit an average of 3 weeks	difference between pre and post driving alertness
Incidents of Adverse events	baseline to end of study. The subjects will be followed for the duration of the clinic visit an average of 3 weeks	safety and tolerability from baseline to end of study
Plasma concentrations of gabapentin	Day 5. The subjects will be followed for the duration of the clinic visit an average of 3 weeks	Plasma concentration of gabapentin on completion of driving test

Trial Locations

Locations (1)

GSK Investigational Site; 🇺🇸 Austin, Texas, United States